← The Wire
RVTYNYSE
REVVITY, INC.
Laboratory Analytical Instruments · MA · CIK 31791
Revvity provides health science solutions, technologies, and services for discovery, development, diagnosis, and cure
🔥 High media attention
$11.12B
Market cap
$111.21
Last close
-1.6%
1D
+12.3%
5D
2.0M
Volume
Price · last 39 sessions+28.6%
May 4L $86.51 · H $113.53Jun 29
262
Total filings
Jun 23, 2026
Last filing
12/29
Fiscal year end
SC 13GSC 13GNov 14, 2024SC 13GJANUS NEWNov 14, 2024SC 13GSC 13GOct 11, 2022SC 13GSC 13GFeb 10, 2022SC 13GSCHEDULE 13GFeb 14, 2018SC 13GRE-FILING UNDER NEW JANUS HENDERSON GROUP PLC POST MERGERFeb 14, 2018SC 13GSC 13G PKI 12.31.17Feb 13, 2017SC 13GSC 13GJan 30, 2017SC 13GPKI AS OF 12/31/2015Feb 12, 2016SC 13GSC 13GFeb 13, 2015SC 13GSC 13GFeb 13, 2014SC 13GPKIJan 8, 2013
Insider Activity
In the 90 days to Feb 24, 2026: 5 sold $4.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 24, 2026 | Victor MiriamePlease See Remarks | Sell | 1,862 | $97.13 | $181K |
| Feb 23, 2026 | Mcmurry-Heath MichelleDirector | Sell | 600 | $97.26 | $58K |
| Feb 5, 2026 | Singh Prahlad R.Please See Remarks | Sell | 12,186 | $99.55 | $1.2M |
| Feb 5, 2026 | Singh Prahlad R.Please See Remarks | Sell | 7,885 | $100.63 | $793K |
| Feb 5, 2026 | Goldberg Joel SPlease See Remarks | Sell | 6,424 | $99.47 | $639K |
| Feb 5, 2026 | Goldberg Joel SPlease See Remarks | Sell | 3,544 | $100.50 | $356K |
| Feb 5, 2026 | Singh Prahlad R.Please See Remarks | Sell | 3,079 | $101.45 | $312K |
| Feb 5, 2026 | Goldberg Joel SPlease See Remarks | Sell | 2,217 | $101.33 | $225K |
| Feb 5, 2026 | Singh Prahlad R.Please See Remarks | Sell | 1,307 | $99.02 | $129K |
| Feb 5, 2026 | Singh Prahlad R.Please See Remarks | Sell | 1,068 | $102.52 | $109K |
| Feb 5, 2026 | Goldberg Joel SPlease See Remarks | Sell | 532 | $102.52 | $55K |
| Feb 2, 2026 | Vohra Tajinder SPlease See Remarks | Sell | 5,756 | $104.50 | $602K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
What Changed
Risk factors · Feb 25, 2025 → Feb 24, 202623 added · 11 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.
Newly disclosed
- Our competitiveness could also be negatively impacted by our failure to timely develop or deploy AI in our products and services, particularly if our competitors are successful in AI advancements in their products and services.
- There is uncertainty related to the legal and regulatory landscape surrounding rapidly evolving AI technologies, particularly in the areas of cybersecurity, intellectual property, and privacy and data protection.
- Tariffs implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million and reduced our gross margin by approximately $20 million, primarily affecting products manufactured in Europe for the U.S. market.
- AI algorithms utilized in the deployment may be flawed or based on datasets that are biased or insufficient, and do not adequately take into account the underlying nature of our business.
- Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation.
- The development and deployment of AI presents both risks and opportunities, and the implementation process could adversely impact the operations of our business as a whole.
- Failure to adequately train our employees during the deployment of AI could adversely impact our business or result in delays or errors in our offerings.
- We are advancing AI across our product and service offerings, and we are in the initial phases of expanding AI into the core functions of our business.
- In 2025, this commitment was reflected in our Great Place to Work certifications across India, China, Poland, and the United States with Euroimmun also certified in Brazil.
- The development of AI technology will require significant investment in resources and human capital and could increase our costs.
- The people experience survey provides additional validation as a substantial majority of our employees report pride in working for Revvity and feel encouraged to innovate and share new ideas, a powerful indicator of shared purpose across our global workforce.
- R ecently announced and proposed changes in U.S. funding and regulations have created a more cautious spending environment for our customers and could cause them to become more conservative with both instrumentation and consumable purchases due to funding and regulatory uncertainty.
No longer disclosed
- The site showcases our commitment to responsible business practices and how these contribute to long-term value creation for our stakeholders. 12 Table of Contents We understand that our ability to operate in a multicultural world is critical to our long-term value creation.
- For our intellectual property that is protected by keeping it secret, such as trade secrets and know-how, we may not use adequate measures to protect this intellectual property. 17 Table of Contents Third parties have in the past and may in the future also challenge the validity of our issued patents, may circumvent or “design around” our patents and patent applications, or claim that our products, processes or technologies infringe their patents.
- We are subject to stringent data privacy and information security laws and regulations and changes in such laws or regulations, or our failure to comply with such requirements, could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
- We believe that our business will continue to be subject to increasing regulation as the federal government continues to strengthen its position on healthcare matters, the scope and effect of which we cannot predict.
- During fiscal year 2024, our voluntary turnover rate was approximately 9%.
- We compete on the basis of service level, price, technological innovation, operational efficiency, product differentiation, product availability, quality and reliability.
- Our growth and profitability are subject to global economic and political conditions, and operational disruptions at our facilities.
- We are also required to meet specified financial ratios under the terms of certain of our existing debt instruments.
- We do not maintain any key person life insurance policies on any of our officers or employees.
- With regards to career growth, we regularly fill open vacancies with internal candidates.
- Our success also depends on our ability to execute leadership succession plans.
In the News
🔥 High media attentionCoverage (30d): 11 reputable articles.
MarketWatchRevvity Inc. stock outperforms competitors despite losses on the day12h agoMarketWatchRevvity Inc. stock outperforms competitors on strong trading day4d agoMarketWatchRevvity Inc. stock underperforms Wednesday when compared to competitors12d agoMarketWatchRevvity Inc. stock underperforms Friday when compared to competitors17d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance